USP18, or Ubiquitin-specific protease 18, serves as a key regulator in the innate immune system, particularly in the context of interferon (IFN) signaling pathways. Its primary function revolves around the negative regulation of type I interferon (IFN-I) signaling, a crucial aspect of the host immune response against viral infections. Upon viral infection or other immune stimuli, cells produce IFN-I, which activates a cascade of signaling events leading to the expression of interferon-stimulated genes (ISGs) involved in antiviral defense mechanisms. USP18 modulates this response by deconjugating the ubiquitin-like protein ISG15 from target proteins, a process known as deISGylation. This action attenuates the antiviral effects of IFN-I signaling by dampening the ISG15ylation of target proteins, thus providing a negative feedback loop to regulate the intensity and duration of the immune response.
Activation of USP18 occurs in response to IFN-I stimulation, whereby increased levels of IFN-I induce the expression and enzymatic activity of USP18. Upon binding to its cognate receptors on the cell surface, IFN-I triggers a signaling cascade that ultimately leads to the activation of transcription factors, such as STAT1 and STAT2, which translocate to the nucleus and promote the expression of ISGs, including USP18. Once expressed, USP18 acts to negatively regulate IFN-I signaling by deconjugating ISG15 from target proteins, thereby suppressing the antiviral response. Additionally, USP18 activation may also be modulated by post-translational modifications or protein-protein interactions, which further fine-tune its enzymatic activity and cellular functions in response to immune stimuli. Overall, the activation of USP18 represents a critical mechanism for regulating the intensity and duration of the innate immune response to viral infections and other pathogens.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Activates USP18 through SIRT1 activation. Resveratrol stimulates SIRT1, leading to increased USP18 expression and enhanced USP18 activity. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
Activates USP18 through AMPK activation. AICAR stimulates AMPK, leading to increased USP18 expression and enhanced USP18 activity. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $186.00 $751.00 | 28 | |
Activates USP18 through BMP pathway modulation. Dorsomorphin inhibits BMP signaling, resulting in increased USP18 expression and activity. | ||||||
Butyric acid | 107-92-6 | sc-214640 sc-214640A | 1 kg 10 kg | $64.00 $177.00 | ||
Activates USP18 through HDAC inhibition. Butyrate inhibits HDACs, leading to increased USP18 expression and enhanced USP18 activity. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Activates USP18 through JAK/STAT pathway modulation. Ruxolitinib inhibits JAK1 and JAK2, resulting in increased USP18 expression and activity. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Activates USP18 through modulation of the NF-κB pathway. Cisplatin influences NF-κB signaling, leading to increased USP18 expression and activity. | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $82.00 $179.00 | 28 | |
Activates USP18 through PPARδ activation. GW501516 modulates PPARδ, leading to increased USP18 expression and enhanced USP18 activity. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Activates USP18 through modulation of the JAK/STAT pathway. Quercetin interferes with JAK/STAT signaling, leading to increased USP18 expression and activity. | ||||||
Histone Lysine Methyltransferase Inhibitor Inhibitor | 935693-62-2 (free base) | sc-202651 | 5 mg | $151.00 | 4 | |
Activates USP18 through inhibition of G9a and GLP histone methyltransferases. BIX-01294 influences histone methylation, leading to increased USP18 expression and activity. | ||||||
Berberine | 2086-83-1 | sc-507337 | 250 mg | $92.00 | 1 | |
Activates USP18 through AMPK activation. Berberine stimulates AMPK, leading to increased USP18 expression and enhanced USP18 activity. | ||||||